Actavis, Incl, Petitioner, v. Julie Demahy

Questions presented

SCOTUS records, cert granted 10 Dec 2010

Are the states preempted under the Supremacy Clause of the Constitution from requiring additional safety information on a generic product label where the brand has not changed its label?

Opinion summary

Etalia.ai summary of the majority opinion

The case involves a dispute over the legality of 'pay-for-delay' agreements, where brand-name drug manufacturers pay generic drug producers to delay entering the market. Actavis and other companies were sued by consumers and advocacy groups for allegedly violating antitrust laws through such settlements. The Federal Trade Commission (FTC) argued that these agreements harm competition and keep drug prices high, while Actavis contended they are legal under patent law as long as they do not extend beyond the patent's scope. The Supreme Court ruled in favor of allowing antitrust challenges to these agreements, stating that large payments from brand-name to generic manufacturers could be indicative of anti-competitive behavior warranting scrutiny under antitrust laws.